หน้าแรก
ค้นหา
Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC
Second-Line Therapy in ALK+ NSCLC
Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC
Dr. Shaw Discusses Efficacy of Lorlatinib in ALK+ NSCLC
Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC
FDA Approval of Brigatinib for ALK+ NSCLC
Sequencing Therapy in ALK+ NSCLC
Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC
Managing Resistance to ALK Inhibitors in NSCLC
Treatment of Newly Diagnosed ALK-Rearranged NSCLC
Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLC
The Founding of ALK Positive
Unmet Needs: Sequencing After Immunotherapy in NSCLC
ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC
Ceritinib and Brain Metastases in NSCLC
Treatment Regimens in NSCLC
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Dr. Perez-Soler on Efficiency of NGS in Lung Cancer
051821 Liu Danny MD JPN FY21 Surgery BariatricSurgery Topical 1740487552
Brief Report: resentibilization to crizotinib by the Lorlatinib alk resistance mutacion L1198F
